Developmental Research Program

发展研究计划（DRP）：项目摘要/摘要 发展研究计划（DRP）将支持遗传学和基因组学的努力， 平滑肌肉瘤（LMS）：提高对癌症生物学的理解和诊断的新方法， 治疗孢子。这种DRP将补充或增强肉瘤转化的多样性和深度， 研究，寻求确保高质量的转化科学研究的持续更新。的DRP 支持短期研究，以建立促进假设驱动的翻译项目所需的数据。 尽管DRP将资助已建立的研究者，但一个重要的目标是确定并激发对以下方面的兴趣： 肉瘤研究的群体，其目前的重点可能是不同的，但充分和过渡相关。 此外，我们寻求吸引早期和中期的职业调查，特别是黑人和拉丁美洲或西班牙裔 investigators.共同指导这一计划将史蒂芬罗宾逊，医学副教授在马约 医学院。罗宾逊博士是牙买加出生的人，在牙买加接受教育。在过去的四年里， 得到了马约诊所职业发展赠款的支持，包括机构K12以及罗伯特 伍德约翰逊基金会阿莫斯医学院发展计划。罗宾逊博士最近接受了 国防部IDEA奖。他还领导了一项ETCTN临床试验，该试验评估了 局部肉瘤的TVEC放射治疗。罗宾逊博士也将参与本次SPORE， 我们努力提高参加临床试验的患者的多样性， 参与的贝克博士是该DRP的联合主任。他是SPORE的首席研究员。贝克博士 对肉瘤的治疗做出了重要贡献， 作为肉瘤患者的有效药物;新辅助治疗策略的制定 骨肉瘤和尤文肉瘤可治愈的疾病。贝克博士有着出色的领导记录， 肉瘤转化研究领域的合作。贝克博士对他的导师工作感到非常自豪。 现在有15位医学教授声称贝克博士是他们的导师。 罗宾逊和贝克加入了一个经验丰富的临床科学家（DRP）的高素质委员会 该委员会负责审查和评价新的试点项目，并根据这些项目向 SPORE执行委员会（主席，Judy Garber）和SPORE MPI，负责选择 适合供资的DRP项目。DRP委员会成员来自主要癌症中心， 拥有肉瘤科学和治疗学关键方面的专业知识，包括生物学和遗传学， 相关科学，肉瘤病理学，分子诊断学，肉瘤耐药性，免疫肿瘤学， 统计设计和分析。DRP将提供在此SPORE中保持创新所需的深度。

Developmental Research Program (DRP): Project Summary / Abstract The Developmental Research Program (DRP) will support the efforts of the Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment SPORE. This DRP will complement or enhance the variety and depth of sarcoma translational research, seeking to ensure continual renewal of high-quality translational scientific investigation. The DRP supports short-range studies to establish the data needed to facilitate hypothesis-driven translational projects. Although the DRP will fund established investigators, an important goal is to identify and stimulate interest in sarcoma research among groups whose current focus may be different but sufficiently and transitionally related. In addition, we seek to attract early and mid- career investigators and especially Black and Latino or Hispanic investigators. Co-directing this program will be Steven Robinson, Associate Professor of Medicine at Mayo School of Medicine. Dr. Robinson is a Jamaican born man educated in Jamaica. For the past 4 years he has been supported by career development grants to Mayo Clinic including the institutional K12 as well as the Robert Wood Johnson Foundation Amos Medical Faculty Development Program. Dr. Robinson is recent recipient of Department of Defense IDEA Award. He also leads a ETCTN clinical trial that evaluates the combination of TVEC with radiation therapy for localized sarcoma. Dr. Robinson will also participate in this SPORE by co-leading our efforts to improve diversity in patients enrolled in clinical trials as well as increasing minority faculty participation. Dr. Baker is the Co-Director of this DRP. He is the SPORE Principal Investigator. Dr. Baker has made important contributions to the treatment of sarcomas beginning with the initial identification of doxorubicin as an effective drug in sarcoma patients; the establishment of neo-adjuvant therapy strategy making osteosarcoma and Ewing sarcoma curable diseases. Dr. Baker has an outstanding record of leadership and collaboration within the sarcoma translational research field. Dr. Baker is most proud of his mentorship efforts. Now 15 Professors of Medicine claim Dr Baker as their mentor. Robinson and Baker are joined by a highly qualified committee of experienced clinician-scientists (DRP Committee) which reviews and evaluates new pilot projects as the basis of providing recommendations to the SPORE Executive Committee (Chair, Judy Garber) and the SPORE MPI, who bear the responsibility to select DRP projects appropriate for funding. The DRP Committee includes members from major cancer centers who possess expertise in key aspects of sarcoma science and therapeutics, including biology and genetics, correlative science, sarcoma pathology, molecular diagnostics, sarcoma drug resistance, immuno-oncology and statistical design and analysis. The DRP will provide the depth required to maintain innovation in this SPORE.